Cholesterol Drug Repatha Slashes Heart Attack Risk By 27 Percent But Disappoints Doctors And Investors Amgen's cholesterol-reducing drug Repatha reduced heart attack rate by 27 percent and stroke by 21 percent. Why are doctors and investors disappointed at the results of the drug's clinical trial? by Allan Adamson
Healthy Living/Wellness Amgen Cholesterol Drug Repatha Turned Down By UK Cost Watchdog by Rina Marie Doctor
Healthy Living/Wellness New Cholesterol Drugs Are Too Expensive: Independent Study Concludes by Ted Ranosa
Healthy Living/Wellness FDA Gives Nod To Praluent: New Class Of Cholesterol-Lowering Drug Is Pricey by James Maynard
Healthy Living/Wellness FDA Panel Pushes For Approval Of Amgen's Cholesterol-Lowering Drug Repatha by Rina Marie Doctor